These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12355106)

  • 21. Biotech's wellspring-a survey of the health of the private sector in 2015.
    Huggett B
    Nat Biotechnol; 2016 Jun; 34(6):608-15. PubMed ID: 27281417
    [No Abstract]   [Full Text] [Related]  

  • 22. Germany biotech gets second chance.
    Sheridan C
    Nat Biotechnol; 2003 Dec; 21(12):1414-5. PubMed ID: 14647310
    [No Abstract]   [Full Text] [Related]  

  • 23. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 24. Writing your business plan.
    Cohen L
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE33-5. PubMed ID: 12089584
    [No Abstract]   [Full Text] [Related]  

  • 25. Biotech marks time in Q3.
    Lawrence S
    Nat Biotechnol; 2005 Nov; 23(11):1332. PubMed ID: 16273049
    [No Abstract]   [Full Text] [Related]  

  • 26. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Realizing potential: the state of Asian bioentrepreneurship.
    Tang CM; Mahmud MA; Foo FK; Chu SY; Chiu RI; Tanticharoen M; Zhang L; Chang TW
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE15-22. PubMed ID: 12874972
    [No Abstract]   [Full Text] [Related]  

  • 28. The nuts and bolts of startups.
    Kiplinger J; Last K
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE29-31. PubMed ID: 12089583
    [No Abstract]   [Full Text] [Related]  

  • 29. A lifeline for the biotech sector.
    Kessel M
    Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
    [No Abstract]   [Full Text] [Related]  

  • 30. Germany reattempts to spark innovation.
    Habeck M
    Nat Biotechnol; 2004 Mar; 22(3):257-8. PubMed ID: 14990939
    [No Abstract]   [Full Text] [Related]  

  • 31. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 32. Commercializing biotechnology in the UK.
    Searle S; Graves B; Towler C
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE33-5. PubMed ID: 12874976
    [No Abstract]   [Full Text] [Related]  

  • 33. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial: Biotech in the financial crisis.
    Jungbauer A
    Biotechnol J; 2009 Aug; 4(8):1095. PubMed ID: 19685457
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF
    Drug Discov Today; 2007 Feb; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract]   [Full Text] [Related]  

  • 36. Strategic consolidation: the biotechnology business model for the 21st century.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE16-7. PubMed ID: 10052317
    [No Abstract]   [Full Text] [Related]  

  • 37. Boardroom tensions rise as investors push for liquidation.
    Orelli B
    Nat Biotechnol; 2009 Jun; 27(6):492-3. PubMed ID: 19513033
    [No Abstract]   [Full Text] [Related]  

  • 38. Private biotech 2004--the numbers.
    Hodgson J
    Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 40. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.